Offensive security in pharmaceutical factories, GxP systems, clinical trials and IP protection.
Why now
Pharma is a priority target of industrial espionage and nation-state actors after molecular IP. Recipe tampering or batch contamination via digital attack can kill. ANVISA does not tolerate GxP non-compliance.
Applicable regulation
/attack-surface
Every engagement is designed for your environment. The points below are part of our standard playbook for this sector — final scope is adapted to your stack and contract.
Pharmaceutical MES, eBR, electronic signature validation.
Laboratory information system, result integrity.
EDC, randomization, IRT, patient data integrity.
Molecule, process and testing market protection.
DataMatrix, aggregation, SNGPC node, ANVISA compliance.
/methodology
Automated scanners find what's documented. Real attackers find what isn't. 90% of the work is manual — performed by specialists holding OSCP, CISSP, CRTO and GPEN.
Target mapping, OSINT, footprint, sector-specific threat modeling.
Deep enumeration, complementary scanning, manual exposure identification.
Manual validation with controlled PoC, finding chaining, escalation.
Executive + technical, step-by-step replication, mapped to applicable regulation.
/why-trust
Engagements in high-criticality healthcare industry.
Technical assessment recognized in highly regulated, mission-critical environments — the pentest that finds what nobody had found before.
Douglas Lopes
Founder · CEO · intrus.io
/faq
Yes. Audit of electronic signature, access control, audit trail, computerized system validation per GAMP 5.
EDC, IRT, randomization and data integrity per ICH GCP and LGPD for sensitive data.
/contact
Schedule a confidential meeting. Within 48h we'll send a proposal with scope, timeline and pricing.